The antibody drug discovery deal between Regeneron Pharmaceuticals Inc. and Sanofi that produced Praluent, Dupixent and Kevzara is to come to an end at the close of 2017, the US company said during its second-quarter results presentation. Regeneron reported a solid second quarter, but investors' eyes glanced over the strong performance for Eylea (aflibercept) to focus rather on how the recent launch of product Dupixent (dupilumab) in atopic dermatitis was faring.
Regeneron's total revenues for the three months ended June 30 were $1.47bn, up 21% on the same quarter last year....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
